Conflicted Safety Panel Let Vioxx Study Continue
Category: Vioxx
More Info: Defective Drugs
In 2004, Merck pulled its painkiller Vioxx from the market. The drug was causing heart problems, strokes and deaths among patients in a large study that was underway at the time. Merck stopped the study early when those results became clear. Thousands of former Vioxx patients and their families are suing the company.
Now, documents obtained by NPR show that five years earlier, in 1999, during another large Vioxx study, patients had similar heart problems. But that study was not stopped.
Q&A: Monitoring Patient Safety
To learn more about data safety monitoring boards and their role in protecting patients who participate in drug studies, NPR turned to statistician David DeMets.
He says the current watchdog system is a good one, but that there are practical limits on the extent to which drug safety can be monitored.
During those five years, millions of Americans took Vioxx. And a Food and Drug Administration scientist has estimated that some 38,000 people who took the drug died.
Q&A: Vioxx Health Risks
Independent analysis of data sent to the FDA show that the cardiovascular risks from Vioxx begin shortly after a patient starts taking the drug. The data also indicate that the risks from Vioxx remain long after patients stop taking the drug.
NPR’s Snigdha Prakash reports on why the earlier study wasn’t stopped and the public warned that Vioxx was unsafe.
Continue reading...
See the full, original post here: https://www.npr.org/templates/story/story.php?storyId=5462419
TriMark Legal Funding was founded in 2003 and is one of America's original legal funding providers. TriMark provides pre-settlement funding and post-settlement funding to injured plaintiffs who are involved in personal injury lawsuits, employment litigation, work injury accidents and workers compensation lawsuits, mass tort litigation, and multidistrict litigation. We also provide post-settlement attorney funding and portfolio funding for law firms.
| Mass Torts Litigation | MDL |
Click here to see the original article.